Toyokawa

This research aims to evaluate tumor samples for transgene levels in patients who have received a commercially available gene modified cellular therapy manufactured by Bristol-Myers Squibb and have developed a qualifying second primary malignancy. The study focuses on patients with conditions such as Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukaemia, and Multiple Myeloma who have undergone this specific gene therapy. Participants received either Idecabtagene vicleucel or Lisocabtagene maraleucel treatments, administered according to their product labels. These are biological therapies produced by Bristol-Myers Squibb. The study involves testing tumor samples using transgene assay methods to analyze the presence and levels of the gene modifications. During the study, researchers will perform participant in situ hybridization (ISH) or droplet-based digital Polymerase Chain Reaction (ddPCR) transgene testing, as well as insertion site analysis (ISA) testing on baseline tumor samples. These tests aim to measure transgene levels in the tumor samples. The study collects and analyzes these results to better understand the gene therapy's impact in patients with a second malignancy.